| Original language | English |
|---|---|
| Pages (from-to) | 2117-2119 |
| Number of pages | 3 |
| Journal | Annals of Hematology |
| Volume | 96 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 01-12-2017 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Interleukin-6 in idiopathic multicentric Castleman’s disease after long-term tocilizumab. / Akiyama, Mitsuhiro; Yasuoka, Hidekata; Takeuchi, Tsutomu.
In: Annals of Hematology, Vol. 96, No. 12, 01.12.2017, p. 2117-2119.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Interleukin-6 in idiopathic multicentric Castleman’s disease after long-term tocilizumab
AU - Akiyama, Mitsuhiro
AU - Yasuoka, Hidekata
AU - Takeuchi, Tsutomu
N1 - Funding Information: Conflict of interest MA has received consultancies, speaking fees, and honoraria from Asahi Kasei Co., Cure Grades Co., and Eisai Co., Ltd., and received research grant from Mitsubishi Tanabe Pharma Co. T.T. has received consulting fees, speaking fees, and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than $10,000 each) and from Chugai Pharmaceutical, Bristol-Myers K.K., Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K., Pfizer Japan, Asahi Kasei Pharma, Takeda Pharmaceutical, AstraZeneca K.K., Eli Lilly Japan K.K., and Novartis Pharma K.K. (more than $10,000 each). Funding Information: We thank Mrs. Keiko Yoshimoto for the assistance of data collection. This study was approved by the institutional ethics committee of Keio University School of Medicine. Informed consent was obtained from all the patients and healthy donors. MA has received consultancies, speaking fees, and honoraria from Asahi Kasei Co., Cure Grades Co., and Eisai Co., Ltd., and received research grant from Mitsubishi Tanabe Pharma Co. T.T. has received consulting fees, speaking fees, and/or honoraria from Pfizer Japan, Mitsubishi Tanabe Pharma, Eisai, Astellas Pharma and UCB (less than $10,000 each) and from Chugai Pharmaceutical, Bristol-Myers K.K., Daiichi Sankyo, AbbVie, Janssen Pharmaceutical K.K., Pfizer Japan, Asahi Kasei Pharma, Takeda Pharmaceutical, AstraZeneca K.K., Eli Lilly Japan K.K., and Novartis Pharma K.K. (more than $10,000 each).
PY - 2017/12/1
Y1 - 2017/12/1
UR - http://www.scopus.com/inward/record.url?scp=85028743843&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028743843&partnerID=8YFLogxK
U2 - 10.1007/s00277-017-3111-x
DO - 10.1007/s00277-017-3111-x
M3 - Letter
C2 - 28861599
AN - SCOPUS:85028743843
VL - 96
SP - 2117
EP - 2119
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
IS - 12
ER -